

Drug Review

Recently Introduced Products

Volume VI, Issue 6

Drug Name	Indication	Potential Plan Impact
Reyataz 300mg capsules	Indicated in combination with other antiretrovirals for the treatment of HIV infections	\$\$
Xyrem 500mg/mL oral solution	For the treatment of cataplexy (a sudden loss of muscle strength) in patients with narcolepsy.	\$\$
Zyprexa 20mg tablets	New Strength - For the acute and maintenance treatment of schizophrenia and related psychotic disorders	\$

\$ Little increase estimated in drug plan expenditure
\$\$ Drug plan expenditure estimated to be somewhat increased
\$\$\$ Potential for large increase in drug plan expenditure

Spriafil™ – Prophylactic and Management Therapy for Invasive Fungal Infections (IFIs)

Spriafil™ oral suspension is the newest antifungal agent for the prophylaxis and treatment of serious fungal infections (such as Aspergillosis and Candidiasis). IFIs are one of the leading causes of death among cancer, HIV, and immunocompromised patients, such as those who receive bone marrow transplantation. The diagnosis of fungal infections, particularly IFIs, is often delayed and difficult to establish with certainty. IFIs are often rather expensive and difficult to treat, with an often poor outcome. The death rate consequential to IFIs ranges from 60% to 90% in the above mentioned special populations.¹

Spriafil™ offers several advantages over currently available antifungal drugs, such as, activity against rare, emerging fungal microorganisms; a superior response to standard intravenous therapies; a preventative therapeutic option due to yeasts and moulds in high risk special populations; a favourable safety profile and an oral dosing option for outpatients.¹

Spriafil™ costs approximately \$23.52 - \$188.20 per day for doses ranging from 100mg to 800mg daily.

ClaimSecure clients will automatically cover Spriafil™ under their existing Open Drug Formularies. For clients that subscribe to ClaimSecure Managed Formularies, Spriafil™ will be placed under Special Authorization. The Special Authorization program will provide plan sponsors an opportunity to ensure that prior to using Spriafil™, their members have tried other optional therapies for each of the approved indications.

If you require additional information about Spriafil™, please contact Shellina Sevany, Manager, Clinical Services Department, at (905) 949-3025 or 1-888-479-7587 ext.3025.

Recommendation: Full Coverage / Special Authorization

ClaimSecure reserves the right to amend in part or in its entirety stated special authorization clinical guidelines

References:

- 1) Schering-Plough Canada Inc., Executive Summary for Spriafil™ Clinical Summary, May 2007.

